PharmaEssentia Past Earnings Performance
Past criteria checks 0/6
PharmaEssentia's earnings have been declining at an average annual rate of -7.4%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 65.1% per year.
Key information
-7.4%
Earnings growth rate
-1.8%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 65.1% |
| Return on equity | -2.6% |
| Net Margin | -12.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?
Apr 02
Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term
Mar 18PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 06Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade
Mar 04PharmaEssentia (GTSM:6446) Is Using Debt Safely
Feb 10What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jan 06
PharmaEssentia Corporation's (GTSM:6446) Profit Outlook
Nov 30Revenue & Expenses BreakdownBeta
How PharmaEssentia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5,106 | -624 | 4,184 | 2,224 |
| 30 Sep 23 | 4,300 | -890 | 4,106 | 2,096 |
| 30 Jun 23 | 3,805 | -1,498 | 3,827 | 1,721 |
| 31 Mar 23 | 3,518 | -1,569 | 3,332 | 1,558 |
| 31 Dec 22 | 2,882 | -1,375 | 2,672 | 1,426 |
| 30 Sep 22 | 2,420 | -2,111 | 2,469 | 1,474 |
| 30 Jun 22 | 1,702 | -2,403 | 2,110 | 1,379 |
| 31 Mar 22 | 811 | -2,669 | 1,809 | 1,334 |
| 31 Dec 21 | 657 | -2,811 | 1,827 | 1,273 |
| 30 Sep 21 | 569 | -2,756 | 1,593 | 1,146 |
| 30 Jun 21 | 610 | -2,673 | 1,457 | 1,083 |
| 31 Mar 21 | 654 | -2,340 | 1,294 | 962 |
| 31 Dec 20 | 557 | -1,948 | 977 | 922 |
| 30 Sep 20 | 464 | -1,204 | 638 | 683 |
| 30 Jun 20 | 332 | -862 | 521 | 552 |
| 31 Mar 20 | 271 | -856 | 495 | 570 |
| 31 Dec 19 | 306 | -843 | 454 | 640 |
| 30 Sep 19 | 130 | -1,113 | 423 | 797 |
| 30 Jun 19 | 129 | -1,080 | 328 | 862 |
| 31 Mar 19 | 61 | -1,086 | 287 | 847 |
| 31 Dec 18 | 26 | -1,040 | 267 | 786 |
| 30 Sep 18 | 4 | -930 | 258 | 695 |
| 30 Jun 18 | 4 | -882 | 239 | 667 |
| 31 Mar 18 | 4 | -878 | 240 | 660 |
| 31 Dec 17 | 4 | -872 | 210 | 683 |
| 30 Sep 17 | 4 | -862 | 189 | 692 |
| 30 Jun 17 | 5 | -898 | 199 | 712 |
| 31 Mar 17 | 6 | -904 | 178 | 737 |
| 31 Dec 16 | 5 | -845 | 167 | 686 |
| 30 Sep 16 | 7 | -892 | 161 | 720 |
| 30 Jun 16 | 9 | -865 | 142 | 709 |
| 31 Mar 16 | 11 | -870 | 126 | 728 |
| 31 Dec 15 | 12 | -853 | 118 | 714 |
| 30 Sep 15 | 9 | -819 | 113 | 701 |
| 30 Jun 15 | 9 | -804 | 105 | 698 |
| 31 Mar 15 | 9 | -796 | 102 | 699 |
| 31 Dec 14 | 13 | -853 | 106 | 765 |
| 30 Sep 14 | 17 | -812 | 127 | 707 |
| 30 Jun 14 | 19 | -833 | 149 | 707 |
| 31 Mar 14 | 46 | -713 | 144 | 619 |
| 31 Dec 13 | 72 | -593 | 139 | 530 |
| 30 Sep 13 | 81 | -449 | 99 | 427 |
| 30 Jun 13 | 89 | -305 | 59 | 324 |
Quality Earnings: 6446 is currently unprofitable.
Growing Profit Margin: 6446 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6446 is unprofitable, and losses have increased over the past 5 years at a rate of 7.4% per year.
Accelerating Growth: Unable to compare 6446's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6446 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.1%).
Return on Equity
High ROE: 6446 has a negative Return on Equity (-2.6%), as it is currently unprofitable.